Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

By H. Scher, M. Morris, W. Stadler, Celestia S. Higano, E. Basch, K. Fizazi, E. Antonarakis, T. Beer, M. Carducci, K. Chi and 25 more. Journal of Clinical Oncology, 2016

1,381 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/3ee2c9c65d1d42865e4f76d6e5a4671284ba2ad7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. N. Mottet
2. Thomas Wiegel

Citations in the corpus

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “Instead, the PCWG2 recommends a combination of bone scintigraphy and CT scans, PSA measurements, and clinical benefit in assessing men with CRPC [116].”
• Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer (2016, neutral): “Blood age, median (range), h 25 (2-78) 27 (1-51) .”